{"nctId":"NCT00786474","briefTitle":"Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)","startDateStruct":{"date":"2009-07"},"conditions":["Arterial Thromboembolic Events","Atrial Fibrillation"],"count":1884,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Dalteparin","type":"EXPERIMENTAL","interventionNames":["Drug: Dalteparin"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Dalteparin","otherNames":["Fragmin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Receiving warfarin therapy for at least 3 months, administered to achieve an international normalized ratio (INR) range of 2.0 to 3.0\n* Requiring temporary interruption of warfarin for pre-specified elective procedure or surgery\n* Presence of one of the following conditions:\n\n  1. Chronic (permanent or paroxysmal) nonvalvular atrial fibrillation, confirmed by at least one prior electrocardiography recording or pacemaker or acid citrate dextrose (ACD) interrogation\n  2. Chronic (permanent or paroxysmal) valvular atrial fibrillation with evidence of mitral valvular heart disease, confirmed by the same criteria as nonvalvular atrial fibrillation\n* Presence of at least one of the following major stroke risk factors:\n\n  1. Older than 75 years of age\n  2. Hypertension\n  3. Diabetes mellitus\n  4. Congestive heart failure or left ventricular dysfunction\n  5. Previous ischemic stroke, systemic embolism, or transient ischemic attack (TIA)\n\nExclusion Criteria:\n\n* Any mechanical prosthetic heart valve\n* Stroke (ischemic or hemorrhagic), systemic embolism, or TIA within the past 12 weeks\n* Venous thromboembolism (deep vein thrombosis and/or pulmonary embolism) within past 12 weeks\n* Major bleeding within the past 6 weeks\n* Severe renal insufficiency, measured through a calculated creatinine clearance of less than 30 mL/min\n* Thrombocytopenia\n* Life expectancy less than 1 month\n* Condition that impairs compliance with trial protocol, such as cognitive impairment, an uncontrolled psychiatric condition, or geographic inaccessibility\n* Pregnancy\n* Allergy to heparin or history of heparin-induced thrombocytopenia\n* Having one of the following surgeries or procedures during warfarin interruption:\n\n  1. Cardiac surgery, such as coronary artery bypass or heart valve replacement\n  2. Neurosurgery that is intracranial or intraspinal, such as tumor resection or aneurysm repair\n  3. High-risk non-surgical procedures, such as brain biopsy\n* Other surgical or non-surgical procedure that, at the discretion of the surgeon, precludes administration of therapeutic-dose low molecular weight heparin (LMWH) at any time in the post-procedure period\n* More than one surgery planned during the trial period\n* Prior participation in this trial","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Arterial Thromboembolic Events","description":"The events are defined as arterial thromboembolism: stokes, transient ischemic attack and systemic embolism events were independently and blindly adjudicated","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Major Bleeding","description":"Major bleeding is defined as symptomatic bleeding associated with transfusion of more than two units of packed red blood cells or whole blood, or death","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Death, Acute Myocardial Infarction, Deep Vein Thrombosis, or Pulmonary Embolism","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Minor Bleeding","description":"Minor bleeding is defined as symptomatic or clinically-overt bleeding that does not satisfy the criteria for major bleeding","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"187","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":66,"n":950},"commonTop":[]}}}